Sept 19 (Reuters) - Medical device maker Axonics has convinced a jury in California federal court that it did not violate rival Medtronic's (MDT.N), opens new tab patent rights in nerve-stimulation ...

Axonics, Inc. AXNX has received regulatory approval from the Therapeutic Goods Administration (TGA) to market its R20 rechargeable sacral neuromodulation (SNM) system in Australia. This cutting-edge ...

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing the Axonics F15™ ...

Axonics devices are implanted to help control incontinence and can last as long as 17 to 24 years or more Boston Scientific Corp. (NYSE: BSX) announced that it has closed on its acquisition of ...

It’s finally over. Medtronic and Boston Scientific’s Axonics longstanding patent battle is finished. The companies settled the legal spat over patent infringements related to sacral neuromodulation ...

Raymond Cohen, co-founder of Axonics, can now breathe a sigh of relief. After a long delay tied to a federal probe of the Axonics sale, Boston Scientific Corp. (NYSE: BSX) announced Nov. 15 the ...

Axonics, Inc. (NASDAQ:AXNX) rose 1.5% in after-hours trading after a jury voted in its favor in a patent dispute with Medtronic (MDT). Medtronic (MDT) was seeking $150 million in a patent dispute with ...

Boston Scientific, a Marlborough medical device manufacturer, has officially closed its acquisition of Axonics, Inc. after entering into a purchase agreement in January. Axonics, a publicly traded ...

Weighted-average shares used to compute basic and diluted net loss per share ...